Please login to the form below
bevacizumab
This page shows the latest bevacizumab news and features for those working in and with pharma, biotech and healthcare.
FDA approves Taiho's stronger Lonsurf regimen for metastatic colorectal cancer
The US Food and Drug Administration (FDA) has approved Taiho Oncology’s Lonsurf (trifluridine and tipiracil) with bevacizumab for use in adults with heavily pre-treated metastatic colorectal cancer (mCRC). ... He added: "Notably, the use of Lonsurf
Latest news
-
Roche reports positive phase 3 data for Tecentriq combination in liver cancer
The analysis of IMbrave050 showed that Tecentriq in combination with Avastin (bevacizumab) significantly improved recurrence-free survival (RFS) in HCC patients with an increased risk of recurrence following resection or ablation
-
Paris Court of Appeal overturns Novartis and Roche’s €444m anti-competitiveness fine
Despite not being approved for wet AMD, Roche’s Avastin (bevacizumab) had been shown in independent trials to be effective in treating the condition and, as the cancer drug is significantly
-
Genentech reports positive phase 3 data for its Tecentriq combination in liver cancer
The pre-specified interim analysis of the IMbrave050 study showed that Tecentriq in combination with Avastin (bevacizumab) significantly improved RFS in HCC patients with an increased risk of recurrence following resection
-
FDA approves ImmunoGen’s Elahere for platinum-resistant ovarian cancer
of FRα and who had been treated with one to three prior systemic treatment regimens – at least one of which included Avastin (bevacizumab).
-
EC approves Celltrion Healthcare’s Vegzelma for multiple cancer types
Celltrion Healthcare’s Vegzelma (CT-P16, biosimilar bevacizumab) has been approved by the European Commission (EC) for the treatment of multiple types of cancer, the company announced. ... Vegzelma is a recombinant humanised monoclonal antibody
More from news
Approximately 21 fully matching, plus 197 partially matching documents found.
Latest Intelligence
-
Cancer immunotherapy: What's on the horizon?
Roche has already chalked up the first successes pairing Tecentriq (atezolizumab) with its veteran anticancer antibody Avastin (bevacizumab) in first-line NSCLC and kidney cancer, with additional trials of the duo
-
Stories that can save lives
Roche instituted similar principles in the promotion of its cancer drug, Avastin (bevacizumab), which works by finding and blocking the blood supply feeding malignant tumors.
-
Pharma deals in July 2015
Still in Japan, a week later AZ agreed a joint venture with Fujifilm Kyowa Kirin Biologics for the development and commercialisation of a biosimilar version of bevacizumab (Avastin) in phase I
-
Current development and marketing of biosimilar monoclonal antibodies in Latin America
NA. Bevacizumab. Biocad. Russia. BCD-021. Clinical. NSCLC: Ph III started in Oct 2012.
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
October 2020: diversity and inclusion in clinical trials round-up
According to their study, Black patients were significantly less likely than white patients to show short-term visual improvement after being given bevacizumab (Avastin), a common treatment used in the
-
The Biosimilar Challenge
These include the infliximab biosimilars Inflectra and Remsima, the etanercept biosimilar Benepali (launched last year) and biosimilars to adalimumab, filgrastim and bevacizumab preparing to launch on the horizon.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Top 10 benefits of virtual advisory boards: Save Time and Resources
- NIHR launches new framework to highlight health progress outcomes
- Johns Hopkins and National Cancer Unit develop new genetic risk-scoring method for major diseases
- UKHSA secures UK-based vaccine deal for future influenza pandemics
- Novo Nordisk and Valo Health agree deal worth up to $3.3bn to develop cardiovascular treatments
- Landscape review reveals £1.1bn of UK funding for rare diseases
No results were found
PMHub
Onyx Health
Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
